RxDoctor Payments Data

Katie Carpenter

Medical · South Charleston, WVNPI 1891108502

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (37.3%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. UCB, Inc. accounts for 65.8% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $9,650, 8.8 times the $1,092 reported in 2021. Among medical clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$26,112in general payments, 2019–2025

Across 561 payments — averaging $46.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$17K
  • Johnson & Johnson$2K
  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Novartis$808
  • Lilly USA, LLC$794
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$7,41428%
  • Speaking & faculty fees$7,22028%
  • Travel & lodging$1,1925%
  • Food & beverage$9,75037%
  • Education$5372%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,112 in reported general payments places this provider in the 95th percentile of 233 medical providers in West Virginia.

See all medical providers in West Virginia

Medicare billing

Part B allowed, 2024
$138,512
Medicare patients
734
Services billed
2,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab28$454,664
TremfyaGuselkumab24$331,566
Dupixent PenDupilumab82$310,575
Taltz AutoinjectorIxekizumab25$193,446
OtezlaApremilast25$106,676
Dupixent SyringeDupilumab14$49,590
Clobetasol Propionate362$16,272
Fluorouracil173$10,799
Triamcinolone Acetonide358$6,845
Ketoconazole215$3,498
Doxycycline Hyclate200$3,193
Tacrolimus11$2,354
Metronidazole46$2,312
Fluocinolone AcetonideFluocinolone/Shower Cap29$1,563
Clindamycin Phosphate27$1,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,030$331,56624 claims
AmgenOtezla$350$106,67625 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 medical providers in West Virginia.

Other medical in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →